This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

proofread

Researchers employ microfluidic diffusional sizing characterize neutralizing antibody affinity to SARS-CoV-2

Researchers employ microfluidic diffusional sizing characterize neutralizing antibody affinity to SARS-CoV-2
Schematic depict of the principles of the neutralizing antibody detection by microfluidic diffusional sizing. Credit: Annals of Biomedical Engineering (2024). DOI: 10.1007/s10439-024-03478-0

SARS-CoV-2 has rampantly spread around the globe and continues to cause unprecedented loss through ongoing waves of (re)infection. Increasing our understanding of the protection against infection with SARS-CoV-2 is critical to ending the pandemic.

Serological assays have been widely used to assess immune responses, but secretory antibodies, the essential first line of defense, have been studied to only a limited extent. Of particular interest and importance are neutralizing antibodies, which block the binding of the spike protein of SARS-CoV-2 to the human receptor angiotensin-converting enzyme-2 (ACE2) and thus are essential for immune defense.

In a study published in Annals of Biomedical Engineering researchers employed microfluidic diffusional sizing (MDS), an immobilization-free technology, to characterize neutralizing antibody affinity to SARS-CoV-2 spike receptor-binding domain (RBD) and spike trimer in .

Affinity measurement was obtained through a contrived sample and buffer using recombinant SARS-CoV-2 RBD and monoclonal antibody. Limited saliva samples demonstrated that MDS applies to saliva neutralizing antibody measurement. The ability to disrupt a complex of ACE2-Fc and trimer is shown. Using a quantitative assay on the patient sample, the researchers determined the affinity and binding site concentration of the neutralizing .

More information: Cara O'Mahoney et al, Microfluidic Diffusional Sizing (MDS) Measurements of Secretory Neutralizing Antibody Affinity Against SARS-CoV-2, Annals of Biomedical Engineering (2024). DOI: 10.1007/s10439-024-03478-0

Journal information: Annals of Biomedical Engineering
Provided by Clemson University
Citation: Researchers employ microfluidic diffusional sizing characterize neutralizing antibody affinity to SARS-CoV-2 (2024, March 26) retrieved 23 May 2024 from https://medicalxpress.com/news/2024-03-employ-microfluidic-diffusional-sizing-characterize.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Antibody that inhibits broad range of sarbecoviruses found

0 shares

Feedback to editors